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Summary
 
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a proapoptotic
member of the TNF family of type II membrane proteins, which constitutes one component of
T cell cytotoxicity. In this study, we investigated the expression and function of TRAIL in hu-
man peripheral blood T (PBT) cells. Although freshly isolated PBT cells did not express a de-
tectable level of TRAIL on their surface, a remarkable TRAIL expression was rapidly induced
on the surface of both CD4
 
1
 
 and CD8
 
1
 
 PBT cells upon stimulation with anti-CD3 mono-
clonal antibody and type I interferons (IFNs). This enhancement of TRAIL expression was a
unique feature of type I IFNs (IFN-
 
a
 
 and IFN-
 
b
 
), and neither type II IFN (IFN-
 
g
 
) nor vari-
ous other cytokines enhanced TRAIL expression on anti-CD3–stimulated PBT cells. Type I
IFNs have been used for clinical treatment of renal cell carcinomas (RCCs), and we found that
most RCC cell lines were susceptible to TRAIL-induced apoptosis. Type I IFNs substantially
augmented cytotoxic activity of anti-CD3–stimulated PBT cells against RCC cell lines in a
TRAIL-dependent manner. These results indicate a unique feature of type I IFNs to regulate
TRAIL-mediated T cell cytotoxicity, which may be involved in the antitumor effects of type I
IFNs against various tumors.
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T
 
umor necrosis factor (TNF)-related apoptosis-induc-
ing ligand (TRAIL)
 
1
 
/APO-2L is a recently identified
type II integral membrane protein belonging to the TNF
family, which induces apoptotic cell death in a variety of
tumor cells (1–3). Among the members of this family, TRAIL
exhibits highest homology to a well-characterized proapop-
totic factor, FasL/CD95L, which has been implicated in T
cell cytotoxicity and immune regulation (4). TRAIL mRNA
was found in a variety of tissues and cells (1), but little is
known about the expression of TRAIL at the protein level
or its physiological functions. Recent studies revealed that
at least four receptors, TRAIL-R1/DR4, TRAIL-R2/
DR5/TRICK2/killer, TRAIL-R3/TRID/DcR1/LIT, and
TRAIL-R4/TRUNDD/DcR2, bind to TRAIL with sim-
ilar affinities (5–10). Both TRAIL-R1 and TRAIL-R2
contain a death domain homologous to that in Fas,
TNFR-I, and DR3/TRAMP/APO-3/WSL-1. Oligomer-
ization of the death domain in TRAIL-R1 and TRAIL-R2
recruits caspase-8 or -10 via Fas-associated death domain
(FADD) or a FADD-like adapter molecule, and activates
the subsequent caspase cascade resulting in apoptotic cell
death (5–8, 10). In contrast to these proapoptotic receptors,
TRAIL-R3 completely lacks a cytoplasmic domain and
exists as a glycophospholipid-anchored protein on the cell
surface. Because TRAIL-R3 can compete with the proap-
optotic TRAIL-Rs for TRAIL binding, it seems to work
as a decoy receptor. It has been suggested that TRAIL in-
 
1
 
Abbreviations used in this paper: 
 
CMA, concanamycin A; CML, chronic
myelogenous leukemia; PBT, peripheral blood T; poly IC, polyinosinic
acid:polycytidylic acid; RCC, renal cell carcinoma; STAT, signal trans-
ducer and activator of transcription; TIL, tumor-infiltrating T lympho-
cyte; TRAIL, TNF-related apoptosis-inducing ligand. 
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duces apoptosis preferentially in transformed cells but not
in normal cells, possibly due to preferential expression of
TRAIL-R3 in the latter (6, 8, 10). TRAIL-R4 carries a
cytoplasmic domain containing a truncated death domain
that cannot transmit a death signal but can activate nuclear
factor 
 
k
 
B, which may protect the cells from TRAIL-R1–
or TRAIL-R2–induced apoptosis (9, 10). To date, the
physiological functions of these multiple TRAIL-Rs re-
main obscure.
It has been shown that CTLs kill target cells by two ma-
jor effector mechanisms, which are mediated by perforin or
FasL (11–13), and that these effector molecules are required
for the elimination of virus-infected cells or certain tumor
cells (14–16). Furthermore, we and others have demon-
strated that these molecules are responsible for mediating
tissue damage associated with T cell–mediated diseases such
as graft-versus-host disease and hepatitis by using murine
models (17–19). In addition to these molecules, we recently
revealed that TRAIL was expressed on human CD4
 
1
 
 T
cell clones and mediated their cytotoxicity against some tu-
mor cells, such as a human T lymphoma Jurkat and a trans-
formed keratinocyte HaCaT (20). Thomas and Hersey also
reported recently that TRAIL at least partly mediated cyto-
toxicity of melanoma-specific CD4
 
1
 
 T cell clones against
some melanoma cells and Jurkat cells (3). These observa-
tions suggested that TRAIL constitutes an additional path-
way of T cell cytotoxicity against certain tumor cells.
However, it remains to be determined whether TRAIL
can be expressed not only on particular T cell clones but
also on circulating T cells and whether it can be used as a
general mechanism of T cell cytotoxicity.
IFNs are the most classical cytokines, and were discov-
ered on the basis of their antiviral activities. It is well
known that a variety of cells produce IFNs in response to
infection by various viruses, bacteria, and mycoplasmas (21,
22). IFNs can be classified into two groups, type I (IFN-
 
a
 
,
IFN-
 
b
 
,
 
 and IFN-
 
v
 
) and type II (IFN-
 
g
 
). All of the type I
IFNs share the same cell surface receptor (IFNAR) com-
posed of at least two subunits, IFNAR-1 and IFNAR-2b/c.
In addition to their antiviral effects, IFNs exhibit pleiotro-
pic biological activities, including antitumor and immuno-
modulatory effects (21, 22). Type I IFNs have been com-
monly used for clinical treatment of certain tumors, including
melanomas, gliomas, chronic myelogenous leukemias (CMLs),
and renal cell carcinomas (RCCs) (23, 24). The antitumor
effects of type I IFNs appear to be mediated by either or
both of the following two mechanisms: (a) direct cytotoxic
or cytostatic activity against tumor cells, and (b) indirect
cytotoxicity by modulating host immune responses. How-
ever, the effector molecules responsible for mediating the
antitumor effects of type I IFNs remain largely unknown.
In this study, we characterized the expression and func-
tion of TRAIL on human peripheral blood T (PBT) cells,
and found a unique feature of type I IFNs to upregulate
TRAIL expression on anti-CD3–stimulated PBT cells. We
also demonstrated that almost all RCC cell lines are suscep-
tible to TRAIL-induced cytotoxicity, and that type I IFNs
augment cytotoxic activity of anti-CD3–stimulated PBT
 
cells against RCC cell lines in a TRAIL-dependent man-
ner. The physiological and clinical relevance of these find-
ings is discussed.
 
Materials and Methods
 
Cells.
 
A human T lymphoma cell line Jurkat was obtained
from Japan Cancer Research Bank and cultured in RPMI 1640
medium containing 10% FCS, 100 
 
m
 
g/ml streptomycin and peni-
cillin, and 2 mM glutamine (culture medium). A mouse B lym-
phoma cell line 2PK-3 was obtained from American Type Culture
Collection and maintained in culture medium. 2PK-3–derived
transfectants, hTRAIL/2PK-3 and hFasL/2PK-3, which stably
express human TRAIL and human FasL, respectively, were pre-
pared as described previously (20) and maintained in culture
medium. Human RCC-derived cell lines 769P, A498, ACHN,
Caki 1, and Caki 2 were obtained from American Type Culture
Collection, and KO-RCC-1 was established as described pre-
viously (25). RCC-derived cell lines KN-39, KN-41, and
OWR-10 were provided by Dr. Y. Kinoshita (Kobe University,
Kobe, Japan). All of these RCC-derived cell lines were main-
tained in culture medium.
 
Reagents.
 
Human IFN-
 
g
 
, TNF-
 
a
 
, IL-4, IL-6, IL-15, and
IL-16 were purchased from PharMingen. Human IL-1
 
a
 
, IL-1
 
b
 
,
and IL-7 were purchased from Genzyme. Human IL-12 was pur-
chased from R&D Systems. Human IL-2, IFN-
 
a
 
, and IFN-
 
b
 
were provided by Shionogi (Osaka, Japan), Sumitomo Pharma
(Osaka, Japan), and Toray (Kamakura, Japan), respectively. Hu-
man IL-18 was provided by Drs. H. Tsutsui, H. Okamura, and
K. Nakanishi (Hyogo College of Medicine, Nishinomiya, Japan).
A synthetic double-stranded RNA, polyinosinic acid:polycytidylic
acid (poly IC), and PHA were purchased from Sigma. Concana-
mycin A (CMA), which inhibits perforin-mediated cytotoxicity
(26), was purchased from Wako Pure Chemicals. An anti-CD28
mAb (CD28.2) was purchased from PharMingen. An anti-CD3
mAb, OKT-3, was prepared from the hybridoma obtained from
American Type Culture Collection. A neutralizing anti–human
FasL mAb (NOK-2, mouse IgG2a/
 
k
 
) and a neutralizing anti–
human TRAIL mAb (RIK-2, mouse IgG1/
 
k
 
) were prepared as
described previously (20, 27).
 
Cell Preparation and Activation.
 
PBMCs were prepared from
healthy volunteers by Ficoll-Hypaque (Sigma) centrifugation.
PBMCs (3 
 
3 
 
10
 
6
 
 cells/ml) were cultured at 37
 
8
 
C for 24 or 48 h
on 24-well plates precoated with 10 
 
m
 
g/ml of anti-CD3 mAb, or
in the presence of IL-2 (500 U/ml), PHA (20 
 
m
 
g/ml), or poly IC
(20 
 
m
 
g/ml).
For preparation of PBT cells, PBMCs were first cultured on
plastic dishes for 1 h at 37
 
8
 
C to deplete adherent monocytes. Af-
ter passage of nonadherent cells through a nylon wool column,
PBT cells were isolated by E-rosetting with sheep red blood cells
followed by depletion of residual NK and B cells by using anti-
CD16 mAb (3G8; PharMingen), anti-CD20 mAb (2H7; Phar-
Mingen), anti-CD56 mAb (B159; PharMingen), and anti–mouse Ig
immunomagnetic beads (Dynal). Purity of PBT cells was 
 
.
 
95%
CD3
 
1
 
 as determined by flow cytometry. In some experiments,
CD4
 
1
 
 and CD8
 
1
 
 T cells were isolated from PBT cells by using
anti-CD4 or anti-CD8 immunomagnetic beads (Dynal) and De-
tachaBead
 
®
 
 (Dynal). The purity of each population was 
 
.
 
98%
CD3
 
1
 
CD4
 
1
 
 or 
 
.
 
98% CD3
 
1
 
CD8
 
1
 
 as estimated by flow cytom-
etry. Purified PBT cells (3 
 
3 
 
10
 
6 
 
cells/ml) were cultured on
plates uncoated or precoated with anti-CD3 mAb (10 
 
m
 
g/ml) in
the presence or absence of IFN-
 
a
 
 (200 U/ml), IFN-
 
b
 
 (200 U/ml),
IFN-
 
g
 
 (500 U/ml), TNF-
 
a
 
 (100 ng/ml), IL-1
 
a
 
 (50 ng/ml), IL-1
 
b 
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(50 ng/ml), IL-2 (500 U/ml), IL-4 (50 ng/ml), IL-6 (200 U/ml),
IL-7 (20 ng/ml), IL-12 (20 ng/ml), IL-15 (150 ng/ml), IL-16
(100 ng/ml), or IL-18 (500 ng/ml) at 37
 
8
 
C for 2 or 48 h. In some
experiments, soluble anti-CD28 mAb (10 
 
m
 
g/ml) was added to
the culture.
 
Flow Cytometric Analysis.
 
Cells (10
 
6
 
) were incubated with 1 
 
m
 
g
of biotinylated RIK-2 or control mouse IgG1 (PharMingen) for
1 h at 4
 
8
 
C followed by PE-labeled avidin (PharMingen). After
washing with PBS, the cells were analyzed on a FACScan™
(Becton Dickinson), and data were processed by using Cell
Quest™ software (Becton Dickinson). In some experiments,
FITC-labeled anti–human CD3 mAb (PharMingen) was included
to identify T cells in PBMCs.
 
Northern Blot Analysis.
 
PBT cells (3 
 
3 
 
10
 
6
 
 cells/ml) were
cultured on plates uncoated or precoated with anti-CD3 mAb
(10 
 
m
 
g/ml) in the presence or absence of IFN-
 
a
 
 (200 U/ml)
for 12 h. Total RNA was then extracted from the cells by using
RNA STAT-60™ (Tel-test, Inc.) according to the manufac-
turer’s instructions. 10 
 
m
 
g each of denatured RNAs was elec-
trophoresed in a 1.5% agarose gel containing 6.6% formalde-
hyde, and then transferred to a nylon membrane (Pall). The
membrane  was hybridized for 4 h with an [
 
a
 
-
 
32
 
P]dCTP-labeled
900-bp XhoI-NotI fragment containing human TRAIL cDNA
(20) at 65
 
8
 
C in ExpressHyb™ hybridization solution (Clontech),
and then washed twice in 2
 
3
 
 SSC/0.1% SDS at 65
 
8
 
C for 15 min
and twice in 0.5
 
3
 
 SSC/0.1% SDS at 65
 
8
 
C for 15 min. The
membrane was analyzed by autoradiography (BAS2500; Fuji
Film, Inc.). In a similar way, the same membrane was rehybrid-
ized with a 1-kb EcoRI-BamHI fragment containing 
 
b
 
-actin
cDNA (28).
 
Cytotoxic Assay.
 
PBT cells (3 
 
3 
 
10
 
6
 
 cells/ml) were prestimu-
lated for 12 h on plates uncoated or precoated with anti-CD3
mAb (10 
 
m
 
g/ml) in the presence or absence of IFN-
 
a
 
 (200 U/ml).
After washing twice with culture medium, the cells were used as
effector cells. In some experiments, human TRAIL or FasL trans-
fectants were used as effector cells.
A 
 
51
 
Cr-release assay was performed as described previously
(29). In brief, 
 
51
 
Cr-labeled target cells (10
 
4
 
) and effector cells
were mixed in U-bottomed wells of a 96-well microtiter plate at
the indicated E/T ratios. After an 8-h incubation, cell-free super-
natants were collected and radioactivity was measured in a
 
g
 
-counter. Percent specific 
 
51
 
Cr release was calculated as de-
scribed (29). In some experiments, the effector cells were pre-
treated with 20 nM CMA for 2 h to inactivate perforin (26).
Anti-FasL mAb (NOK-2) and/or anti-TRAIL mAb (RIK-2)
 
were added to a final concentration of 10 
 
m
 
g/ml each at the start
of the cytotoxic assay.
 
Results
 
Expression of TRAIL on Anti-CD3– and IFN-
 
a
 
–stimulated
PBT Cells.
 
We recently demonstrated that human CD4
 
1
 
T cell clones constitutively expressed TRAIL on their sur-
face as estimated by staining with neutralizing anti-TRAIL
mAbs, RIK-1 and RIK-2 (20). In contrast, as represented
in Fig. 1, we could not find a detectable level of surface
TRAIL on freshly isolated PBT cells. Because the expres-
sion of TNF family proteins such as TNF-
 
a
 
 and FasL can
be induced on activated T cells, we examined whether sur-
face TRAIL expression can be also upregulated on PBT cells
by various stimuli. PBMCs were stimulated with immobi-
lized anti-CD3 mAb, PHA, IL-2, or poly IC for 24 or 48 h,
and TRAIL expression on CD3
 
1
 
 PBT cells was then ex-
amined by flow cytometry with RIK-2 mAb. As repre-
sented in Fig. 1, no detectable level of TRAIL was found
on PBT cells when stimulated with PHA or IL-2. In con-
trast, marginal but significant levels of TRAIL expression
were consistently observed upon stimulation with anti-CD3
mAb or poly IC.
Since poly IC has been known to be a potent inducer of
type I IFNs (21, 22), we next examined whether IFN-
 
a
 
can directly affect TRAIL expression on PBT cells. As repre-
sented in Fig. 2 A, marginal but significant levels of TRAIL
expression were observed on both CD4
 
1
 
 and CD8
 
1
 
 PBT
cells at 12 h after stimulation with either anti-CD3 mAb or
IFN-
 
a
 
 alone. Interestingly, the combination of anti-CD3
mAb and IFN-
 
a
 
 greatly upregulated TRAIL expression on
both CD4
 
1
 
 and CD8
 
1
 
 PBT cells. Similar results were ob-
tained at 24 or 48 h after each stimulation (data not shown).
These results indicated that stimulation with anti-CD3
mAb alone is not sufficient for maximal induction of sur-
face TRAIL expression on PBT cells, and that IFN-
 
a
 
 pro-
vides a costimulatory signal that synergistically upregulates
TRAIL expression.
It has been shown that expression of some TNF family
proteins such as CD40L on activated T cells was upregu-
Figure 1. Expression of TRAIL
on human PBT cells. PBMCs
were cultured for the indicated
time periods on plates precoated
with anti-CD3 mAb (10 mg/ml)
or in the presence of PHA (20
mg/ml), IL-2 (500 U/ml), or
poly IC (20 mg/ml). The cells
were then stained with biotiny-
lated RIK-2 followed by PE-
labeled avidin and FITC-labeled
anti-CD3 mAb. Solid lines,
staining with RIK-2 on CD31
PBT cells. Dotted lines, back-
ground staining with biotiny-
lated control IgG and PE-labeled
avidin. Similar results were ob-
tained with PBT cells from three
individuals. 
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lated by a CD28-mediated costimulatory signal (30). There-
fore, we tested whether the CD28-mediated costimulation
might affect expression of TRAIL on anti-CD3–stimulated
PBT cells. As represented in Fig. 2 A, the addition of an
agonistic anti-CD28 mAb barely affected the expression
levels of surface TRAIL on anti-CD3– or anti-CD3 plus
IFN-
 
a
 
–stimulated PBT cells, indicating that the CD28-
mediated costimulatory signal does not contribute to TRAIL
induction in PBT cells.
We also examined the kinetics of TRAIL expression af-
ter stimulation with anti-CD3 plus
 
 IFN-a. As represented
in Fig. 2 B, TRAIL expression appeared on both CD41 and
CD81 PBT cells at 2 h after stimulation, and reached a peak
at 6 h. Similar levels of surface TRAIL expression were re-
tained on CD41 and CD81 PBT cells at 48 h (not shown).
Characterization of Cytokines that Can Regulate TRAIL Ex-
pression. We next examined various cytokines for their
ability to regulate TRAIL expression on unstimulated or
anti-CD3–stimulated PBT cells. IFN-b, another type I IFN
that shares the same receptor (IFNAR) with IFN-a (21,
22), exhibited a similar effect as IFN-a, which alone in-
duced a marginal TRAIL expression on PBT cells and
greatly upregulated TRAIL expression on anti-CD3–stim-
ulated PBT cells (Fig. 3). Similar levels of TRAIL expres-
Figure 2. Regulation of surface TRAIL expression on human CD41 or CD81 PBT cells by TCR/CD3 and/or IFN-a. (A) Purified CD41 or CD81
PBT cells were cultured for 12 h on plates uncoated or precoated with anti-CD3 mAb (10 mg/ml) in the presence or absence of IFN-a (200 U/ml) and/
or soluble anti-CD28 mAb (10 mg/ml), and then stained with biotinylated RIK-2 and PE-avidin (solid lines). Dotted lines, background staining with bio-
tinylated control IgG and PE-avidin. Similar results were obtained with CD41 or CD81 T cells from three individuals. (B) Time course of TRAIL ex-
pression on human CD41 or CD81 PBT cells after stimulation with anti–CD3 plus IFN-a. CD41 or CD81 PBT cells were cultured on plates precoated
with anti-CD3 mAb (10 mg/ml) in the presence of IFN-a (200 U/ml). After the indicated time periods, the cells were stained with biotinylated RIK-2
and PE-avidin (solid lines). Dotted lines, background staining with biotinylated control IgG and PE-avidin. Similar results were obtained with CD41 or
CD81 T cells from three individuals.1455 Kayagaki et al.
sion on anti-CD3–stimulated PBT cells were observed upon
costimulation with a lower dose of IFN-a and IFN-b (50
U/ml; not shown). In contrast, the type II IFN (IFN-g),
which stimulates a distinct receptor (IFNGR), exhibited no
effect on TRAIL expression on unstimulated or anti-CD3–
stimulated PBT cells at 12 h (Fig. 3) or 24 or 48 h (not shown)
even at a high dose of 500 U/ml. We also examined IL-2,
IL-15, IL-12, and IL-18, which have been reported to up-
regulate FasL expression on T and NK cells (4, 31–33), but
observed no effect on TRAIL expression (Fig. 3). Similarly,
no effect was observed with the other cytokines tested, in-
cluding TNF-a, IL-1a, IL-1b, IL-4, IL-6, IL-7, and IL-16
(data not shown). These results indicated that the ability to
induce TRAIL expression on PBT cells is a unique feature of
type I IFNs.
Transcriptional Regulation of TRAIL Expression in PBT Cells
by TCR/CD3 and/or Type I IFNs. It has been reported
that TRAIL mRNA was detectable in a variety of tissues
and cells (1). Furthermore, a recent study demonstrated
TRAIL mRNA expression in human PBT cells after acti-
vation with anti-CD3 mAb or PMA plus ionomycin (34).
Therefore, we examined whether stimulation with anti-
CD3 mAb and/or IFN-a upregulates TRAIL expression
in PBT cells at the transcriptional level. As represented in
Fig. 4, PBT cells cultured with medium alone expressed
only a marginal level of the 1.6-kb TRAIL transcript. Al-
though stimulation with either IFN-a or anti-CD3 mAb
alone significantly increased TRAIL mRNA expression, a
remarkable increase was observed after stimulation with the
combination of anti-CD3 mAb and IFN-a. It was also
noted that IFN-a was more effective than anti-CD3 mAb
in inducing TRAIL mRNA expression when used alone.
Similar results were obtained when PBT cells were stimu-
lated with IFN-b (not shown). These results indicated that
type I IFNs regulate TRAIL expression in unstimulated or
anti-CD3–stimulated PBT cells at the transcriptional level.
Figure 3. Regulation of TRAIL expres-
sion on human PBT cells by various cyto-
kines. PBT cells were cultured for 12 h on
plates uncoated or precoated with anti-CD3
mAb (10 mg/ml) in the presence or absence
of IFN-a (200 U/ml), IFN-b (200 U/ml),
IFN-g (500 U/ml), IL-2 (500 U/ml), IL-12
(20 ng/ml), IL-15 (150 ng/ml), or IL-18
(500 ng/ml). The cells were then stained
with biotinylated RIK-2 and PE-avidin
(solid lines). Dotted lines, background stain-
ing with biotinylated control IgG and PE-
avidin. Similar results were obtained with
PBT cells from three individuals.
Figure 4. Northern blot analysis of TRAIL mRNA expression in PBT
cells. PBT cells were cultured for 12 h with medium alone (2), IFN-a
(200 U/ml), and/or immobilized anti-CD3 mAb (10 mg/ml). Total
RNAs were extracted from the cells, and 10 mg each was subjected to
Northern hybridization with human TRAIL cDNA probe (top). The
blot was subsequently rehybridized with b-actin cDNA probe (bottom).
Similar results were obtained with PBT cells from two individuals.1456 Regulation of TRAIL-mediated T Cell Cytotoxicity by Type I IFNs
Involvement of TRAIL in IFN-a–enhanced T Cell Cytotox-
icity against RCC Cell Lines. Type I IFNs have been used
for clinical treatment of various tumors, including melano-
mas, gliomas, CMLs, and RCCs (23, 24). The unique fea-
ture of type I IFNs to upregulate TRAIL expression on
PBT cells prompted us to examine whether IFN-induced
TRAIL on PBT cells might be directly involved in en-
hanced cytotoxicity against tumor cells. In this respect, we
first examined the susceptibility of human RCC cell lines
to cytotoxicity by human TRAIL transfectants. We also
examined their susceptibility to human FasL, which consti-
tutes another pathway of T cell cytotoxicity. As repre-
sented in Fig. 5, eight out of nine RCC cell lines tested
were sensitive to TRAIL-induced cytotoxicity. Some RCC
cell lines (A498 and KN-41) exhibited as high sensitivity as
Jurkat, which has been commonly used as a highly sensitive
target for TRAIL (1–3). On the other hand, the FasL trans-
fectants lysed five out of nine RCC cell lines, all of which
were also lysed by the TRAIL transfectants. Some RCC
cell lines (Caki 1, KN-39, and KN-41) were sensitive to
TRAIL but not to FasL.
We then examined the cytotoxic activity of anti-CD3–
and/or IFN-a–stimulated PBT cells against RCC cell lines
that were sensitive to both TRAIL and FasL (ACHN and
A498) or sensitive to TRAIL but resistant to FasL (KN-39
and KN-41). A neutralizing anti-TRAIL mAb (RIK-2
[20]) and a neutralizing anti-FasL mAb (NOK-2 [27]) were
used to assess the contribution of TRAIL and FasL to the
cytotoxicity. CMA pretreatment, which inactivates per-
forin (26), was used to assess the contribution of perforin.
As shown in Fig. 6, anti-CD3–stimulated PBT cells exhib-
ited substantial cytotoxic activities against both types of
RCC target cells, which were partially inhibited by RIK-2
but not by NOK-2; the residual cytotoxicity was mostly
abrogated by CMA treatment, indicating that these cyto-
toxic activities were mediated by TRAIL and perforin. Al-
though IFN-a stimulation alone did not significantly in-
duce cytotoxicity, costimulation with IFN-a greatly enhanced
the cytotoxic activities of anti-CD3–stimulated PBT cells;
this enhancement was abrogated by RIK-2 but not by
NOK-2, indicating that the IFN-a–enhanced cytotoxicity
was predominantly mediated by TRAIL but not by FasL. It
was also noted that the TRAIL-independent residual cyto-
toxic activities, which were abrogated by CMA treatment,
were almost comparable between the anti-CD3–stimulated
T cells and the anti-CD3 plus IFN-a–stimulated T cells,
indicating that IFN-a did not enhance perforin-mediated
cytotoxicity. These results indicate that IFN-a can aug-
ment the cytotoxic activity of TCR/CD3-stimulated PBT
cells against RCC cells by specifically enhancing TRAIL-
mediated cytotoxicity.
Discussion
We recently demonstrated that human CD41 T cell
clones constitutively expressed TRAIL, which was fully re-
sponsible for spontaneous cytotoxicity against certain tu-
mor cells, such as Jurkat cells (20). Others have also re-
cently shown that the cytotoxic activity of human CD41 T
cell clones against melanoma cells was at least partly medi-
ated by TRAIL (3). In this study, we characterized the ex-
pression and function of TRAIL on human PBT cells and
found that both CD41 and CD81 PBT cells express TRAIL
upon TCR/CD3 stimulation, especially in the presence of
type I IFNs. This indicated that TRAIL-mediated cytotox-
icity is not confined to particular T cell clones but can be
generally involved in TCR/CD3-mediated, antigen-speci-
fic cytotoxicity exerted by human T cells, especially when
they are exposed to exogenously administrated or endoge-
nously produced type I IFNs.
A previous study by others demonstrated the upregulation
of TRAIL mRNA in human PBT cells after activation with
anti-CD3 mAb or PMA plus ionomycin (34). In the present
study, we demonstrated that anti-CD3 stimulation induced
surface TRAIL expression on human PBT cells but only
marginally. We found that IFN-a greatly enhanced TRAIL
expression on anti-CD3–stimulated PBT cells, whereas
IFN-a solely induced TRAIL expression on PBT cells and
only marginally. This enhancement of TRAIL expression
was a unique feature of type I IFNs (IFN-a and IFN-b)
among the various cytokines so far tested. Other cytokines
that have been shown to upregulate FasL expression in T
and NK cells (IL-2, IL-12, IL-15, and IL-18 [4, 31–33]) or
those enhancing T cell cytotoxicity (IL-2, IL-4, IL-6, IL-7,
IL-12, IL-15, and IL-18) did not affect TRAIL expression
on unstimulated or anti-CD3–stimulated PBT cells. North-
ern blot analysis showed that the synergistic effect of anti-
CD3 and IFN-a was exerted at the transcriptional level. A
higher transcriptional induction by IFN-a alone than that
by anti-CD3 alone suggests the possibility that TRAIL
gene expression is primarily regulated by IFN-a and that
anti-CD3 stimulation may act synergistically by upregulat-
Figure 5. Cytotoxic activity of TRAIL or FasL transfectants against
RCC cell lines. Cytotoxic activity of hTRAIL/2PK-3 (black bars),
hFasL/2PK-3 (hatched bars), or 2PK-3 (white bars) was tested against the
indicated target cells by 8 h 51Cr-release assay at an E/T ratio of 10. Data
represent mean 6 SD of triplicate samples. Similar results were obtained
in two independent experiments.1457 Kayagaki et al.
ing type I IFN receptors (IFNARs) on PBT cells. Binding
of type I IFN to IFNAR leads to activation of the recep-
tor-associated tyrosine kinases, Tyk-2 and Jak-1, which
phosphorylate signal transducer and activator of transcrip-
tion (STAT)-1 and STAT-2. Phosphorylated STAT-1 and
STAT-2 form a transcriptionally active heterotrimer com-
plex (ISGF3) together with ISGF3g/p48, which binds to a
cis-acting enhancer sequence termed IFN-stimulated re-
sponse element (ISRE [35]). Over 30 proteins have been
known to be the products of type I IFN–inducible genes
whose transcription can be upregulated by ISRE in the
flanking region (21, 22). Further studies are needed to
characterize the regulatory region of the TRAIL gene and
to elucidate the regulatory mechanisms for TRAIL expres-
sion at the transcriptional level.
Type I IFNs have been commonly used for clinical treat-
ments of certain tumors, including melanomas, gliomas,
CMLs, and RCCs (23, 24). However, the majority of these
tumors are resistant to type I IFN-induced growth arrest or
apoptosis in vitro. Previous studies in the mouse system
have shown that the antitumor effect of type I IFNs in vivo
was mediated by host T cells (36, 37). Furthermore, the
combination of type I IFNs and adoptive transfer of tumor-
specific T cells was effective for rejection of certain tumors
(38, 39). Although it is well known that type I IFNs exert
pleiotropic immunomodulatory effects including upregula-
tion of MHC class I expression and enhancement of CTL
cytotoxicity (21, 22), the effector molecules responsible for
mediating the antitumor effects of type I IFNs have not
been well characterized. In this study, we revealed that type I
IFNs upregulate TRAIL expression on TCR/CD3-stimu-
lated T cells and augment their cytotoxicity against TRAIL-
sensitive tumor cells. We found that almost all of the RCC
cell lines tested were TRAIL sensitive, and that IFN-a sub-
stantially enhanced the cytotoxic activity of TCR/CD3-
stimulated PBT cells against these target cells in a TRAIL-
Figure 6. Involvement of TRAIL, FasL, or perforin in anti-CD3– and/or IFN-a–stimulated T cell cytotoxicity against RCC cell lines. PBT cells were
stimulated with immobilized anti-CD3 mAb (10 mg/ml) and/or IFN-a (200 U/ml) for 12 h. Cytotoxic activity was then tested against ACHN, A498,
KN-39, or KN-41 target cells in the presence or absence (black bars) of 10 mg/ml each of RIK-2 (alone, hatched bars), NOK-2 (alone, white bars),
RIK-2 and NOK-2 (striped bars), or RIK-2 and NOK-2 with 20 nM CMA (gray bars) by 8 h 51Cr-release assay at an E/T ratio of 30. Data represent
mean 6 SD of triplicate samples. Similar results were obtained in three independent experiments.1458 Regulation of TRAIL-mediated T Cell Cytotoxicity by Type I IFNs
dependent manner. Moreover, a recent study by Thomas
and Hersey demonstrated that most of the melanoma cell
lines they tested were also sensitive to TRAIL-induced ap-
optosis (3). Therefore, it is possible that the enhancement
by IFN-a of TRAIL-mediated cytotoxicity by TCR/
CD3-stimulated T cells at least partly accounts for the anti-
tumor effects of type I IFNs against RCCs and melanomas.
It is known that melanomas and RCCs are highly anti-
genic, and tumor-infiltrating T lymphocytes (TILs) are fre-
quently observed in patients with RCCs or melanomas (40,
41). In such a situation, the administration of type I IFNs
would upregulate TRAIL expression on TCR/CD3-stim-
ulated TILs that are reactive to some tumor antigen and
thus augment their cytotoxicity against TRAIL-sensitive
tumor cells. Type I IFNs would also upregulate MHC class I
expression on tumor cells and thus enhance TCR/CD3-
mediated upregulation of TRAIL expression on tumor-reac-
tive T cells. In addition, it has been shown that the combi-
nation of type I IFNs and certain chemotherapeutic drugs
exerts synergistic antitumor effects (23, 24). In this respect,
it is noteworthy that the expression of a proapoptotic
TRAIL receptor, TRAIL-R2/DR5/killer, can be upregu-
lated in some tumor cells by chemotherapeutic drugs in a
p53-dependent manner (7). Therefore, it is possible that
the synergistic antitumor effects of type I IFNs and some
chemotherapeutic drugs may be at least partly mediated by
TRAIL induction by the former and TRAIL-R2 induc-
tion by the latter.
It is known that T cell cytotoxicity is mediated by per-
forin and FasL (11–13). Our present study demonstrated
that TRAIL constitutes an additional predominant pathway
of T cell cytotoxicity potentially against various tumor
cells. However, the expression of these effector molecules
in PBT cells is differently regulated. We showed previously
that the expression of perforin in PBT cells is confined to a
minor population of CD81 T cells that express CD11b and
represent memory effector CTLs (29). We also demonstrated
previously that FasL is not expressed on PBT cells but can be
transiently expressed on CD45RO1 memory CD41 and
CD81 T cells upon stimulation with PMA plus ionomycin
or anti-CD3 mAb (42). However, the cell surface expression
of FasL on activated T cells is rapidly downregulated by
shedding mediated by some proteases (27). Also in the
present study, we examined FasL expression in anti-CD3–
and/or IFN-a–stimulated PBT cells (data not shown). Re-
hybridization of the Northern blot shown in Fig. 4 with a
human FasL cDNA probe showed that FasL mRNA ex-
pression was induced by anti-CD3 but not by IFN-a,
and no enhancement of anti-CD3–induced FasL mRNA
expression was observed upon costimulation with IFN-a.
However, we could not find a detectable level of cell sur-
face FasL expression on the anti-CD3–stimulated PBT
cells, possibly due to the rapid shedding. Consequently, we
could not find a substantial contribution of FasL to the cyto-
toxic activities of anti-CD3– and/or IFN-a–stimulated
PBT cells even against the FasL-sensitive target cells (A498
and ACHN; Fig. 6). In contrast to this transient nature of
FasL expression, TRAIL can be stably expressed on most
CD41 and CD81 T cells, especially when costimulated
with anti-CD3 and IFN-a (Fig. 2 B). This suggests that
TRAIL can mediate more long-lasting T cell cytotoxicity
than FasL, which would be beneficial for exerting an anti-
tumor effect. In the case of FasL, the rapid downregulation
by shedding has been suggested to be beneficial for avoid-
ing normal tissue damage, such as in hepatitis (43, 44). In
contrast, it has been shown that TRAIL exerts no apparent
toxicity in vivo (44). Therefore, the specific upregulation
of TRAIL by type I IFNs can be expected to augment T
cell cytotoxicity against tumor cells without harmful effects
on normal tissues.
Although this study demonstrated a potential role of
TRAIL in mediating T cell cytotoxicity against tumor
cells, physiological and pathological roles of TRAIL-medi-
ated T cell cytotoxicity remain largely unknown. It is well
known that type I IFNs can be inducible by infection of
various viruses, bacteria, and mycoplasmas (21, 22). In this
respect, TRAIL-mediated T cell cytotoxicity may play an
important role in clearance of virus- or intracellular organ-
ism–infected cells, which has been shown to be dependent
on type I IFNs but not on perforin or FasL (14, 45). It is
also interesting to note that TRAIL might be involved in
the pathogenesis of AIDS. Recently, Jeremias et al.  re-
ported that PBT cells from HIV-infected patients but not
those from healthy individuals were susceptible to TRAIL-
induced apoptosis (34). Since elevated serum levels of IFN-a
were found during HIV infection (46), it is possible that
type I IFN-induced, TRAIL-dependent T cell cytotoxicity
might be involved in clearance of HIV-infected cells or in
the pathogenesis of AIDS and HIV-associated diseases. This
notion is further supported by a recent report showing a
contribution of TRAIL to anti-CD3–induced apoptosis of
PBT cells from HIV-infected patients (47). Further studies
are now underway to address these issues.
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